Department of Neurology, Fenghua District People's Hospital of Ningbo, Zhejiang, China.
Clin Neuropharmacol. 2020 Nov/Dec;43(6):191-195. doi: 10.1097/WNF.0000000000000417.
The efficacy of lasmiditan is used to alleviate migraine. We conduct a systematic review and meta-analysis to explore the influence of lasmiditan versus placebo on pain control in patients with migraine.
We search the PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through June 2020 for randomized controlled trials (RCTs) assessing the effect of lasmiditan versus placebo on pain control in patients with migraine. This meta-analysis was performed using the random effects model.
Four randomized controlled trials are included in the meta-analysis. Overall, compared with the control group, in patients with migraine, lasmiditan treatment shows positive impact on pain free at 2 hours [risk ratio (RR), 1.74; 95% confidence interval (CI), 1.47-2.07; P < 0.00001], headache response at 2 hours (RR, 1.38; 95% CI, 1.28-1.49; P < 0.00001), pain free at 24 hours (RR, 1.55; 95% CI, 1.16-2.07; P = 0.003), and no or mild disability level (RR, 1.20; 95% CI, 1.11-1.29; P < 0.00001), but has no obvious influence on nausea (RR, 2.22; 95% CI, 0.92-5.35; P = 0.08). In addition, lasmiditan seems to result in the increase in dizziness (RR, 6.36; 95% CI, 3.00-13.46; P < 0.0001) and paresthesia (RR, 5.10; 95% CI, 2.66-9.78; P < 0.00001).
Lasmiditan treatment provides additional benefits for pain control in patients with migraine.
拉米替坦用于缓解偏头痛。我们进行了一项系统评价和荟萃分析，以探讨拉米替坦与安慰剂相比对偏头痛患者疼痛控制的影响。
我们检索了 PubMed、EMbase、Web of Science、EBSCO 和 Cochrane 图书馆数据库，截至 2020 年 6 月，以评估拉米替坦与安慰剂相比对偏头痛患者疼痛控制效果的随机对照试验（RCT）。本荟萃分析采用随机效应模型进行。
共有 4 项 RCT 纳入荟萃分析。总体而言，与对照组相比，偏头痛患者接受拉米替坦治疗在 2 小时时无疼痛[风险比（RR），1.74；95%置信区间（CI），1.47-2.07；P<0.00001]、2 小时时头痛缓解（RR，1.38；95%CI，1.28-1.49；P<0.00001）、24 小时时无疼痛（RR，1.55；95%CI，1.16-2.07；P=0.003）和无或轻度残疾水平（RR，1.20；95%CI，1.11-1.29；P<0.00001）方面有积极影响，但对恶心无明显影响（RR，2.22；95%CI，0.92-5.35；P=0.08）。此外，拉米替坦似乎会导致头晕（RR，6.36；95%CI，3.00-13.46；P<0.0001）和感觉异常（RR，5.10；95%CI，2.66-9.78；P<0.00001）的发生率增加。
拉米替坦治疗可为偏头痛患者的疼痛控制提供额外益处。
